The hemodynamic and antithrombotic properties of prostacyclin (PGI2) were evaluated in an in vivo canine model in which left circumflex coronary artery (LCX) thrombus formation was initiated by electrical stimulation (150 iA, DC for 6 hours) of the artery's intimal surface via an implanted silver wire electrode. Eleven of the 12 control dogs (92%) developed totally occlusive LCX thrombi after an average of 3.2 + 0.4 hours of LCX stimulation; the remaining control dog underwent spontaneous ventricular fibrillation.
NATURALLY OCCURRING prostaglandins have been intensively studied to characterize their complex effects on the cardiovascular system and to apply some of their unique pharmacologic properties to specific clinical cardiovascular problems. Prostacyclin (PGI2) has been of particular interest since its dis-covery1 because it can prevent24 or reverse, 6 in vivo platelet aggregation and has potent vasodilatory effects. In addition, investigations in the cat7' 8 and the dog" have demonstrated that PGI2 has a protective effect on myocardium subjected to ischemia. The results of these and numerous other studies have prompted suggestions that PGI2 may have clinical value in the management of specific cardiovascular diseases.
Recognition of the importance of circulating platelets in the pathogenesis of coronary artery thrombosis has stimulated the search for pharmacologic agents that can prevent extensive platelet aggregation in response to thrombogenic stimuli. The advantages of using a naturally occurring platelet-aggreg'Ation inhibitor led us to evaluate the in vivo antithrombotic properties of PGI2. By chest dogs. This experimental approach allowed us to evaluate the antithrombotic and hemodynamic impact of prolonged PGI2 infusion. The results presented in this report demonstrate the marked antithrombotic and hemodynamic effects of PGIa in an animal model of coronary artery thrombosis.
Methods

Surgical Preparation
Thirty-seven male mongrel dogs that weighed 18-20 kg were used. Each dog was anesthetized with sodium pentobarbital (30 mg/kg, i.v.), intubated and placed on positive-pressure respiration. A left thoracotomy was performed at the fifth intercostal space and the pericardium was incised. An apical stab wound in the left atrial appendage permitted the insertion of a cannula (PE 260) used to infuse PGI2. Distal to the atrial branch and proximal to its first descending branch, 1-2 cm of the LCX were isolated from surrounding tissue by careful blunt dissection. Within this isolated region, an electromagnetic flow probe was affixed to the artery for continuous measurement of LCX blood flow. To aid in the insertion of the LCX stimulating electrode, the tip of a 25-gauge hypodermic needle was secured to the leading end of the 28-gauge Tefloncoated silver wire. This electrode was inserted through the wall of the LCX so that the tip of the electrode (2-3 mm) was in contact with the intimal lining of the vessel. The electrode was connected in series to a 250,000-Q potentiometer, a 9-V nickel-cadmium battery and a digital ammeter. The circuit was completed by suturing a disc electrode to a subcutaneous region on the chest wall. The stimulating circuit was designed to permit constant monitoring and easy adjustment of the direct anodal current delivered to the intimal surface of the LCX.
Hemodynamic data were recorded continuously during the course of the experiment on a six-channel 906 PGI2 IN CORONARY ARTERY THROMBOSIS/Romson et al.
Grass polygraph. Arterial blood pressure was measured with a Statham pressure transducer attached to a polyethylene catheter advanced to the abdominal aorta by way of the right femoral artery. Epicardial electrograms were obtained by suturing a monopolar electrode in the region of the left ventricular myocardium perfused by the LCX. Segmental left ventricular isometric contractile force in the region of the myocardium dependent on LCX flow was measured with a Brodie-Walton strain-gauge arch. Replicate thermodilution cardiac output determinations were made every 30 minutes throughout the experiment. After completion of the surgical preparation, each dog received a supplemental dose of sodium pentobarbital (5 mg/kg, i.m.) to maintain a stable level of anesthesia. Thirty minutes were allowed at the conclusion of the surgical preparation for each dog to stabilize.
Initiation of PGI, Infusion and LCX Stimulation
After basal hemodynamic measurements were recorded, a continuous infusion of PGI2 (150, 300 or 500 ng/kg/min) or drug diluent (50 mM isotonic Tris-HCI buffer, pH 9.4 at 4°C) was started into the left atrial appendage. The constant infusion rate of 0.5 ml/min was maintained by a peristaltic pump, which was calibrated at the start of each experiment. PGI2 solutions in 50 mM isotonic Tris-HCl (pH 9.4) were made daily from crystalline sodium PGI2 and maintained on ice (0-4°C) during the 6-hour infusion. Ten minutes after the start of infusion, electrical stimulation of the LCX was initiated at 150 ,uA via the implanted silver wire electrode. Stimulation of the LCX and left atri-al infusion of PGI2 or Tris buffer were continued for 6 hours. Immediately before sacrifice by electrical fibrillation, a 20% patent blue violet solution (1 ml/5 kg body weight) was injected into the left atrial appendage. Introduction of this flow-dependent dye into the myocardial circulation permitted postmortem quantification of the extent of left ventricular myocardium that was not receiving coronary blood flow as a result of LCX coronary artery thrombosis.
After removal of the heart, the LCX was dissected free of surrounding tissue and opened lengthwise. Adhering thrombotic material was removed from the intimal surface of the LCX to determine thrombus wet weight. The heart was sectioned transversely from apex to base in l.0-cm-thick rings. The nonperfused regions of left ventricular myocardium, identified by the absence of patent blue violet, were dissected free of surrounding myocardium and weighed. The amount of the nonperfused tissue is expressed as a percent of the total left ventricular mass.
LCX Microscopy
LCX samples for light microscopy were prepared by fixation for 2 hours at room temperature in a solution of 2.5% glutaraldehyde (V/V) and 2% paraformaldehyde (W/V) in 0.1 M cacodylate buffer (pH 7.4). The samples were then transferred to 10% sucrose in 0.1 M cacodylate buffer (pH 7.4) and stored at 4°C. Samples to be examined by scanning electron microscopy were postfixed for 1 hour in 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4), dehydrated in a graded series of ethanol solutions and desiccated by critical-point drying. After the samples had been coated with gold, they were examined with an AMR 1200 scanning electron microscope.
Statistics
Except where otherwise noted, all data were analyzed using an analysis of variance software package available through the Michigan Terminal System. A p value less than 0.05 was considered significant. Data are expressed as the mean + SEM unless noted otherwise.
Results
Low-amperage electrical stimulation of canine LCX consistently produces occlusive coronary artery thrombosis in dogs receiving a drug-free infusion of Tris buffer (controls). In this report, occlusive LCX thrombosis is determined primarily on the basis of total cessation of LCX blood flow. The time when thrombotic occlusion of the vessel occurred is readily determined by continuously monitoring LCX blood flow. A typical sequence of the hemodynamic changes associated with thrombotic occlusion of the LCX in control dogs is shown in figure 1 . Complete cessation of LCX blood flow occurred after 1 hour and 15 minutes of stimulation. However, signs of developing ischemia are evident as early as 45 minutes into the stimulation period. At this time, a reduction in left ventricular isometric force in the LCX perfused region of myocardium, an alteration in the phasic coronary blood flow wave form and a reduction in mean coronary blood flow are evidence that LCX thrombosis is occurring. After 47 minutes of stimulation, ST-segment elevation can be seen in the epicardial electrode situated in the LCX dependent region of the myocardium. In addition, left ventricular force in this region is further diminished. Complete LCX occlusion by intravascular thrombosis occurs at 1 hour and 15 minutes of LCX coronary artery stimulation. Further elevation of the epicardial electrogram ST segments appear as LCX flow is reduced to zero.
Isometric left ventricular contractile force, as measured by the Brodie-Walton strain gauge, is markedly altered. Instead of active development of force, the ischemic myocardium is undergoing passive bulging in response to intraventricular pressure increases occurring during systole (at 1 hour, 15 minutes). The average time to complete LCX occlusion in the control dogs was 3. The most notable effect of PGI2 at this dose is the marked reduction in arterial blood pressure. The epicardial electrogram remained normal over the entire stimulation period and mean LCX blood flow was increased. Left ventricular isometric force declined slightly over the course of the experiment. In short, infusion of PGI2 prevented occlusive LCX thrombosis, avoiding the ischemia-induced deterioration of regional myocardial performance seen in figure 1. Figure 3 indicates the changes in LCX blood flow in each dog of the control and PGI2 (500 ng/kg/min) treatment groups. In the control dogs, LCX blood flow steadily declined until there was complete cessation of blood flow through the coronary artery. Eleven of the 12 control animals (92%) developed occlusive thrombi; the other dog in the group developed spontaneous ventricular fibrillation 4 hours into the experiment. The average time to complete thrombotic occlusion of the LCX, based on these coronary blood flow data, was 3.2 + 0.4 hours (range 1.25-5 hours). Infusion of PGI2 at a dose of 500 ng/kg/min prevented the decline and eventual cessation of LCX blood flow characteristic of the control dogs.
The hemodynamic effects of a 6-hour infusion of PGI2 at doses of 150, 300 or 500 ng/kg/min are summarized in figure 4 . The data in the lower left corner of figure 4 show the mean changes in LCX blood flow for each of the four treatment groups. In the control dogs, coronary blood flow progressively declined. Infusion of PGI2 (150, 300 or 500 ng/kg/min) prevented the reduction in LCX blood flow seen in the control dogs.
The dose-dependent reduction in arterial blood pressure was rapid, with the maximal effect occurring within 10 minutes after the initiation of infusion ( fig.  4 ). Arterial blood pressure remained depressed for the entire period of PGI2 infusion. After 6 hours of PGI2 infusion at a dose of 500 ng/kg/min, mean arterial pressure was reduced by 36 ± 4% relative to the preinfusion basal readings. Upon termination of the infusion, mean arterial pressure returned toward basal levels. Cardiac output was increased by 51 ± 14% over basal readings after 6 hours of infusion of PGI2 at a dose of 500 ng/kg/min ( fig. 4 ). PGI2 infusion at 300 ng/kg/min significantly increased cardiac output. No dose-dependent relationship was found between PGI2 and heart rate. At a dose of 300 ng/kg/min of PGI1, heart rate increased, but at doses of 150 and 500 ng/kg/min, the heart rates were not significantly different from those of control dogs. The increase in heart rate seen in control dogs between 4 and 6 hours is probably the result of enhanced sympathetic activity in response to regional myocardial ischemia produced by coronary artery thrombosis. Whereas the PGI-induced alterations in heart rate are relatively small and inconsistent and no increase in left ventricular isometric force was seen, the marked increase in cardiac output is attributed mainly to the reduction in outflow impedance resulting from the hypotensive properties of PG12. properties of PGI2. Figure 5 is a light micrograph of two LCX arteries, one from a dog that received drugfree Tris buffer infusion and the other from a PGO2treated dog (500 mg/kg/min). The arteries were sectioned transversely, immediately distal to the site at which the electrode was introduced into the lumen of the artery. The lumen of the vessel from the control dog is distended and completely filled with thrombotic material deposited in response to intimal injury caused ..-S1 \v4y t) FIGURE 5. Light micrographs of left circumflex coronary arteries (LCX) transversely sectioned immediately distal to the electrode insertion site, from a control dog (vehicletreated) and a dog that received PGI2 at a dose of 500 ng/kg/min for 6 hours. The wire electrode was removed before sectioning. The lumen of the vesselfrom the control dog is filled with thrombotic material deposited in response to electrical injury of the LCX. The vessel from the PGI2treated dog has partially collapsed and the lumen contains a small amount of thrombotic material. The schematic diagrams to the right of the tissue sections were added for clarity (tissue sections magnified X8).
trol and PGI2-treated dogs (500 ng/kg/min) are shown in figures 6 and 7. The coronary arteries were prepared by opening the vessel longitudinally, revealing the lumen of the LCX at the site of electrode insertion. Figure 6A shows an occlusive thrombus mass within the lumen of an LCX removed from a control dog. Distal to the site of electrode insertion (asterisk) the thrombus is lightly colored and marked with interspersed, dark transverse bands. A scanning electron micrograph of the region of the thrombus indicated by the asterisk is shown in figure 6B . Large platelet aggregates, fibrous material and trapped erythrocytes can be seen in this high-power field. The proximal portion of the thrombus (fig. 6A ) is much darker. This region is composed almost entirely of erythrocytes (red thrombus), resulting from stasis of blood flow. Platelet aggregates adhering to the damaged endothelium of the vessel and thrombus formation caused enough disruption of coronary blood flow to permit stasis coagulation. Figure 7A , a low-power scanning electron micrograph of the luminal surface of the LCX from a dog receiving PGI2 (500 ng/kg/min), reveals the potent antithrombotic properties of PGI. After 6 hours of electrical stimulation of the LCX, there is a lesion on the intimal surface, but little thrombotic material has been deposited. Injury of this magnitude would be expected to induce platelet aggregation and thrombus formation. Figure 7B Because a discrete variable (occluded or nonoccluded) of small sample size was being analyzed, binomial expansion was deemed the proper method of determining statistical significance. The middle columns represent the wet weight of the intravascular thrombus developed in response to 6 hours of LCX stimulation at 150 MA. The columns on the right indicate the extent ofleft ventricular ischemia as delineated by the injection of patent blue violet before sacrifice (see Methods section). Analysis of variance was used to evaluate the statistical significance of thrombus wet weight and percent of left ventricular ischemia. Data are mean ± SD. Significant differences from the control dogs are indicated by an asterisk.
ng/kg/min, 19%; and at 500 ng/kg/min, 9%. PGI, infusion reduced intraluminal thrombus mass in a doserelated manner. The control dogs had an average thrombus wet weight of 50 ± 8 mg. The groups treated with PGI, at 150, 300 or 500 ng/kg/min had average thrombus wet weights of 20 ± 5, 13 ± 4 and 3 2 mg, respectively. Immediately before sacrifice, the flow-dependent dye, patent blue violet, was injected into the left atrial appendage. This technique allows visualization of regions of myocardium not receiving blood flow due to deposition of thrombotic material in the lumen of the LCX. The extent of myocardial ischemia is significantly reduced in all PGI,-treated groups as compared with the control group (fig. 8 ). PGI, possesses in vivo antithrombotic properties. It prevents occlusive thrombosis, decreases thrombus mass, and limits the percent of the left ventricle rendered ischemic due to thrombus formation.
Discussion
The results presented in this report clearly demonstrate the marked antithrombotic properties of PGI, infusion in an in vivo model of coronary artery thrombosis. Folts et al.1' developed a technique for producing cyclic alterations in canine LCX blood flow due to platelet aggregates by narrowing the lumen of the vessel with a plastic occluder. Using this technique, Aiken et al.'2 demonstrated a reduction in the frequency of occlusive episodes with PGI2 infusion, indicating that in vivo platelet aggregation is inhibited by PGI2.
Our model may more realistically simulate human coronary artery thrombus formation, as intimal injury produced by low-amperage electrical stimulation of the LCX induces platelet adhesion and secondary recruitment of platelets to form aggregates. The initial platelet thrombus is stabilized by incorporating fibrin into the growing thrombus mass. The thrombus has an intravascular mass similar in morphology and composition to human coronary artery thrombi ( fig.  6 ).13 Thus, the reported method of inducing coronary artery thrombosis provides a more appropriate model to study the antithrombotic properties of compounds like PGI2.
In this animal model, constant infusion of PGI1 at a dose of 500 ng/kg/min inhibited in vivo platelet aggregation and consistently prevented thrombotic occlusion of the LCX at the site of electrically induced intimal injury. Eleven of 12 control dogs (92%) and one of 11 PGI2-treated dogs (500 ng/kg/min) (9%) developed occlusive LCX thrombi. Cessation of LCX blood flow during the course of the experiment was used as an indication of thrombotic occlusion. Postmortem examination of the LCX revealed that in dogs in which cessation of LCX coronary blood flow occurred, intravascular thrombi completely filled the arterial lumen. However, in those animals in which LCX coronary blood flow was unaltered over the course of the experiment, nonocclusive mural thrombi were found ( fig. 5 ). This progressive decline and ultimate cessation of LCX blood flow correlates with complete thrombotic filling of the vascular lumen.
The vasodilating properties of PGI2 may have played a role in maintaining LCX blood flow by relaxing vascular tone, permitting blood to flow between the arterial wall and thrombus mass. However, in a series of preliminary experiments, a brief infusion of PGI2 (500 ng/kg/min) after thrombotic occlusion of the LCX was never observed to increase blood flow through the vessel (unpublished observations). In addition, the marked differences noted between PGI2treated and control animals with respect to intravascular thrombus mass ( fig. 8 ) and morphology (figs. 5-7) suggest that PGI1 prevents occlusion of the LCX primarily by inhibiting thrombus formation at the site of intimal injury.
The hemodynamic effects of PGI2 when administered as a 6-hour infusion are, for the most part, similar to results after a short exposure to the drug.' 164 PGI is a potent vasodilator and produces a dose-dependent reduction in arterial blood pressure.
Other investigators'5 16 the initial 10 minutes of infusion. However, the trend over the 6-hour infusion period was toward elevated heart rates. The pronounced increases in cardiac output with PGI2 administration in this study differ somewhat from the inconsistent effects reported elsewhere.',, 1 ' The primary difference between these reports is the method of administration of PGI2. Before the present report, most investigators have relied on bolus injections or short-term infusions of PGI2. The continuous infusion of PGI2 over 6 hours permitted the experimental preparation to stabilize from the drastic initial hemodynamic effects of PGI2 administration. In summary, the prolonged, constant infusion of PGI at various dosage levels provided considerable information on the effects of PGI2 on various hemodynamic measurements.
Our primary concern in this study was to evaluate the antithrombotic properties of PGI2. However, we felt it was more appropriate to study the hemodynamic impact of prolonged PGI2 infusion during active coronary artery thrombosis than to study the agent in an experimental model in which the coronary circulation remains unperturbed. Despite the complications introduced into the interpretation of hemodynamic data obtained during coronary artery thrombosis and subsequent regional myocardial ischemia, this experimental approach more closely parallels the clinical setting in which PGI2 may be used in the management of human coronary artery thrombosis.
Our data indicate that PGI2 is not the ideal therapy for treatment of arterial thromboembolic conditions. Chemical instability and short biologic half-life demand careful attention to formulation conditions (pH 9.4 at 4°C) and constant infusion to achieve a desired antithrombotic effect. In addition, the marked vasodilatory actions of PGI2 have a significant impact on cardiac hemodynamics. The potent vasodepressor effects of PGI2 may be limiting, especially in patients with coronary artery disease in whom a reduction in coronary perfusion pressure may precipitate myocardial ischemia. In this study, a dose of 500 ng/kg/min was necessary to reliably prevent coronary artery thrombosis. This dose resulted in a dramatic reduction in arterial blood pressure. A dose of 50 ng/kg/min has produced signs of cardiovascular collapse in healthy volunteers.'7 However, to facilitate the use of this experimental model, we had to induce occlusive thrombus development over a reasonably short period. Thus, the stimulus necessary to reproducibly induce this occlusive event would a priori be more drastic than naturally occurring arterial thrombogenic stimuli, and logically, would require more aggressive pharmacologic intervention.
Nevertheless, PGI2 may have considerable therapeutic value. In addition to its antithrombotic actions, recent data indicate a protective effect on ischemic myocardium.79 Platelets have been postulated to play a role in the formation of arteriosclerotic lesions,'8' 1' and there have been reports of a reduction in vascular PGI2 synthesis in atherosclerotic vessels. [20] [21] [22] This may suggest that PGI2 can be used as a prophylactic treatment against progressive arteriosclerosis. One of the earliest reports of successful clinical application of PGI2 in treating peripheral vascular disease came from Szczeklik et al. 23 Five patients with advanced arteriosclerosis obliterans experienced a significantly improved clinical status with prolonged PGI2 infusion. 23 Two general schemes may be anticipated for improving the clinical acceptability of PGI2. First, the concomitant use of a phosphodiesterase inhibitor, such as theophylline or dipyridamole, may be expected to potentiate the effect of PGI2 in inhibiting platelet aggregation by maintaining elevated intracellular platelet cAMP levels. Evidence obtained in vitro24 and in the rabbit28 indicate that phosphodiesterase inhibitors prolong the platelet inhibitory and antithrombotic properties of PGI2, respectively. Preliminary, unpublished data in the model detailed in this report indicate that the concomitant use of aminophylline as a phosphodiesterase inhibitor permits a 10fold reduction in the amount of PGI2 necessary to prevent coronary artery thrombosis. Thus, one may significantly reduce the dose of PGI2 and, in turn, reduce its adverse hemodynamic impact while still maintaining its antithrombotic actions.
The second approach toward improving the clinical value of PGI2 would be the development of stable PGI2 analogs. Many investigators are attempting to manipulate the structure of PGI2 to enhance its biologic stability. However, for the most part, PGI2 analogs that possess prolonged in vitro antiplatelet aggregating activity generally are as short-lived as natural PGI2 in vivo.28' 27 But it appears to be only a matter of time before a useful PGI2 analog with in vivo platelet inhibitory properties and minimal vasodepressor effects is developed and used to treat human thrombotic disorders.
